Acute Myeloid Leukemia (AML)

Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse

Posttransplantation, glasdegib maintenance therapy in patients at high risk for relapse did not meaningfully reduce relapse incidence.Use of glasdegib in the posttransplantation setting was complicated by adverse events requiring drug holds and occasional discontinuation.

Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML)

The implementation of next-generation sequencing (NGS) has influenced diagnostic, prognostic, and therapeutic decisions in myeloid malignancies. However, the clinical relevance of serial molecular annotation in patients with myelodysplastic syndrome (MDS) undergoing active treatment is unknown.

HDAC4 inhibition disrupts TET2 function in high-risk MDS and AML

Aberrant DNA methylation often silences transcription of tumor-suppressor genes and is considered a hallmark of myeloid neoplasms. Similarly, histone deacetylation represses transcription of genes responsible for cell differentiation/death. A previous clinical study suggested potential pharmacodynamic antagonism between histone deacetylase inhibitors (HDACi) and DNA hypomethylating agents (HMA).

Thomas G. DeLoughery, MD, MACP, FAWM

Institution
Oregon Health & Science University
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Chronic Lymphocytic Leukemia (CLL)
Chronic Myelomonocytic Leukaemia (CMML)
Graft Versus Host Disease (GVHD)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Pure Red Cell Aplasia (PRCA)
About
Tom DeLoughery is a native Hoosier who graduated from Indiana State University in 1981 (one year after Larry Bird) and the Indiana University School of Medicine in 1985. He did his internship at the University of California, Irvine before traveling to Oregon where he finished his internal medicine residency and hematology/oncology fellowship. He is currently a professor of medicine, pathology and pediatrics in the Divisions of Hematology/Oncology and Laboratory Medicine at OHSU. His clinical interests are in blood diseases, hemostasis, and thrombosis, subjects on which he has written

Catherine Broome, MD

Institution
MedStar Health - Georgetown
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Chronic Lymphocytic Leukemia (CLL)
Chronic Myelomonocytic Leukaemia (CMML)
Graft Versus Host Disease (GVHD)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Pure Red Cell Aplasia (PRCA)
About
Catherine M. Broome, MD, is board certified in internal medicine, hematology and medical oncology. She has been on staff at the MedStar Georgetown University Hospital's Lombardi Comprehensive Cancer Center for eight years. A fascination with the science of hematology and the opportunity to develop a strong relationship with patients and their families led Dr. Broome to specialize in hematology and medical oncology. Dr. Broome focuses on developing a partnership with her patients, providing them the most up-to-­date information and treatment options. They work together to develop a treatment

Matt Kalaycio, MD

Institution
Cleveland Clinic Taussig Cancer Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Chronic Lymphocytic Leukemia (CLL)
Chronic Myelomonocytic Leukaemia (CMML)
Graft Versus Host Disease (GVHD)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Pure Red Cell Aplasia (PRCA)
About
Matt Kalaycio, MD, FACP, is the former Chairman of the Department of Hematology and Medical Oncology at Cleveland Clinic Taussig Cancer Institute. Dr. Kalaycio is also a Professor in the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. Board-certified in hematology, Dr. Kalaycio's clinical interests are in leukemia and hematopoietic cell transplantation. Dr. Kalaycio has published over 200 articles in numerous scientific publications including Bone Marrow Transplantation, Journal of Clinical Oncology, and Leukemia. He serves on the editorial board of Biology of

Ryan J. Mattison, MD

Institution
University of Wisconsin Health
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Chronic Lymphocytic Leukemia (CLL)
Chronic Myelomonocytic Leukaemia (CMML)
Graft Versus Host Disease (GVHD)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Pure Red Cell Aplasia (PRCA)
About
Dr Mattison is an associate professor of medicine within the division of hematology/oncology at the University of Wisconsin School of Medicine and Public Health. He earned his medical degree at the University of Iowa Carver College of Medicine, Iowa City, IA. He completed his residency at University of North Carolina Hospitals, Chapel Hill, NC and his fellowship at the University of Chicago Hospitals, Chicago, IL. Dr. Mattison is board-certified in internal medicine, medical oncology and hematology.

Cecilia Arana Yi, MD, MSHS, FACP

Institution
Mayo Clinic, Phoenix, AZ
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Chronic Lymphocytic Leukemia (CLL)
Chronic Myelomonocytic Leukaemia (CMML)
Graft Versus Host Disease (GVHD)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Pure Red Cell Aplasia (PRCA)
Subscribe to Acute Myeloid Leukemia (AML)

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.